H.C. Wainwright analyst Matthew Caufield raised the firm’s price target on Mineralys Therapeutics (MLYS) to $42 from $30 and keeps a Buy rating on the shares. The firm cites “consistent” key opinion leader support for the lorundrostat ASI approach to hypertension for the target increase. The analyst is “enthusiastic” for lorundrostat “supporting a differentiated and viable path forward” for treating hypertension patients.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MLYS:
- 3 Best Stocks to Buy Now, 4/1/2025, According to Top Analysts
- Mineralys Therapeutics Unveils Promising Trial Results for Lorundrostat
- 3 Best Stocks to Buy Now, 3/31/2025, According to Top Analysts
- Mineralys Therapeutics presents results from Phase 2 Advance-HTN trial
- Promising Clinical Trial Results and Safety Profile of Lorundrostat Support Buy Rating for Mineralys Therapeutics
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue